Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Roland Wolf

Showing results (91-100 of 159) with videos related to

Pageof 16
Sort By:
The Biochemical Journal|December 17, 2002
Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activityJack U Flanagan, Lesley A McLaughlin, Mark J I Paine, et al.
The Journal of Biological Chemistry|May 25, 2013
The involvement of mitochondrial amidoxime reducing components 1 and 2 and mitochondrial cytochrome b5 in N-reductive metabolism in human cellsBirte Plitzko, Gudrun Ott, Debora Reichmann, et al.
Chemico-Biological Interactions|September 10, 2025
Integration of in vivo stress reporters with transcription profiling to define chemical mixtures mechanisms of toxicity, including trans-generational effectsFrancisco Inesta-Vaquera, Wenduo Qi, Silviya Dimova-Vasileva, et al.
Pharmacogenetics and Genomics|September 6, 2005
No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinomaLouise E McGreavey, Faye Turner, Gillian Smith, et al.
Molecular Pharmacology|June 2, 2011
Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse lineMaki Hasegawa, Yury Kapelyukh, Harunobu Tahara, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 13, 2015
Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse ModelNico Scheer, Yury Kapelyukh, Anja Rode, et al.
Analytical Biochemistry|April 16, 2003
Quantitation of cytochrome P450 mRNA levels in human skinLilian G Yengi, Qian Xiang, Jinmei Pan, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
No association of polymorphisms in CYP17, CYP19, and HSD17-B1 with plasma estradiol concentrations in 1,090 British womenRuth C Travis, Michael Churchman, Sarah A Edwards, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|February 4, 2006
Hepatic cytochrome P-450 reductase-null mice show reduced transcriptional response to quercetin and reveal physiological homeostasis between jejunum and liverDavid M Mutch, Vanessa Crespy, Jennifer Clough, et al.
The Journal of Investigative Dermatology|July 26, 2003
Quantitative real-time reverse transcription-polymerase chain reaction analysis of drug metabolizing and cytoprotective genes in psoriasis and regulation by ultraviolet radiationGillian Smith, Robert S Dawe, Colin Clark, et al.
Pageof 16

Showing results (91-100 of 159) with videos related to

Sort By:
Pageof 16
The Biochemical Journal|December 17, 2002
Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activityJack U Flanagan, Lesley A McLaughlin, Mark J I Paine, et al.
The Journal of Biological Chemistry|May 25, 2013
The involvement of mitochondrial amidoxime reducing components 1 and 2 and mitochondrial cytochrome b5 in N-reductive metabolism in human cellsBirte Plitzko, Gudrun Ott, Debora Reichmann, et al.
Chemico-Biological Interactions|September 10, 2025
Integration of in vivo stress reporters with transcription profiling to define chemical mixtures mechanisms of toxicity, including trans-generational effectsFrancisco Inesta-Vaquera, Wenduo Qi, Silviya Dimova-Vasileva, et al.
Pharmacogenetics and Genomics|September 6, 2005
No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinomaLouise E McGreavey, Faye Turner, Gillian Smith, et al.
Molecular Pharmacology|June 2, 2011
Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse lineMaki Hasegawa, Yury Kapelyukh, Harunobu Tahara, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 13, 2015
Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse ModelNico Scheer, Yury Kapelyukh, Anja Rode, et al.
Analytical Biochemistry|April 16, 2003
Quantitation of cytochrome P450 mRNA levels in human skinLilian G Yengi, Qian Xiang, Jinmei Pan, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
No association of polymorphisms in CYP17, CYP19, and HSD17-B1 with plasma estradiol concentrations in 1,090 British womenRuth C Travis, Michael Churchman, Sarah A Edwards, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|February 4, 2006
Hepatic cytochrome P-450 reductase-null mice show reduced transcriptional response to quercetin and reveal physiological homeostasis between jejunum and liverDavid M Mutch, Vanessa Crespy, Jennifer Clough, et al.
The Journal of Investigative Dermatology|July 26, 2003
Quantitative real-time reverse transcription-polymerase chain reaction analysis of drug metabolizing and cytoprotective genes in psoriasis and regulation by ultraviolet radiationGillian Smith, Robert S Dawe, Colin Clark, et al.
Pageof 16